Holen Sie sich die Stockscreener-App
0.539
5.11%
-0.029
Handel nachbörslich:
.53
-0.009
-1.67%
Schlusskurs vom Vortag:
$0.568
Offen:
$0.5513
24-Stunden-Volumen:
167.91K
Relative Volume:
1.33
Marktkapitalisierung:
$8.75M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-16.26M
KGV:
-0.4562
EPS:
-1.1814
Netto-Cashflow:
$-13.50M
1W Leistung:
-5.92%
1M Leistung:
-72.22%
6M Leistung:
-83.67%
1J Leistung:
-85.66%
1-Tages-Spanne:
$0.53
$0.5679
1-Wochen-Bereich:
$0.53
$0.5925
52-Wochen-Spanne:
$0.50
$5.275
Intensity Therapeutics Inc Stock (INTS) Company Profile
Firmenname
Intensity Therapeutics Inc
Sektor
Branche
Telefon
203-221-7381
Adresse
1 ENTERPRISE DRIVE, SUITE 430, SHELTON
Vergleichen Sie INTS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
INTS
Intensity Therapeutics Inc
|
0.539 | 8.75M | 0 | -16.26M | -13.50M | -1.1814 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Intensity Therapeutics Inc Aktie (INTS) Neueste Nachrichten
Intensity Therapeutics (INTS) Expands Cancer Trial to France | INTS Stock News - GuruFocus
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Receive European Medicines Agency Authorization to Initiate Phase 2 INVINCIBLE-4 (SAKK/66/22) Study for INT230-6 in the Treatment of Presurgical Triple-Negative Breast - PR Newswire
Cholangiocarcinoma Clinical Trials and Studies 2025: EMA, - openPR.com
Cholangiocarcinoma Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - Barchart.com
Offerings News Live Feed - Stock Titan
Intensity Therapeutics, Inc. Announces the Closing and Full Exercise of the Over-Allotment Option from its Upsized Initial Public Offering, Raising a Total of $22.425 Million in Gross Proceeds - Barchart.com
Intratumoral Cancer Therapies Market Predicted to See Upsurge - openPR.com
Post-Trade Analysis: Intensity Therapeutics Inc (INTS) Climbs 12.57, Closing at 0.64 - DWinneX
Daily Market Movement: Lexeo Therapeutics Inc (LXEO) Sees a -3.53 Decrease, Closing at 3.55 - DWinneX
Closing Bell Recap: Greenlane Holdings Inc (GNLN) Ends at 0.01, Reflecting a -3.23 Downturn - DWinneX
In the Green: TMD Energy Ltd (TMDE) Closes at 1.58, Up/Down 5.33 from Previous Day - DWinneX
Navigating INTS’s Stock Market Maze: Ups and Downs in 2023 - investchronicle.com
The Business Case For Buying Intensity Therapeutics Inc (NASDAQ: INTS) Stock Now - Stocksregister
Intensity Therapeutics plunges on $2.35M public offering - MSN
US Stock Futures Dip As Oil Prices Continue To Slide - Finimize
Analysts Conflicted on These Healthcare Names: Regeneron (REGN), Community Health (CYH) and Integer Holdings (ITGR) - The Globe and Mail
United States shares higher at close of trade; Dow Jones Industrial Average up 0.05% - Investing.com India
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.05% - Investing.com
Intensity Therapeutics sets terms for $2.35 million offering - Investing.com
Shelton biotech eyes $2.35M public offering to fund research - Hartford Business Journal
Intensity Therapeutics (INTS) Launches Public Offering to Raise $2.35 Million | INTS Stock News - GuruFocus
Why Intensity Therapeutics (INTS) Stock Is Getting Hammered - Benzinga
Intensity Therapeutics, Inc. Announces $2.35 Million Public Offering - Nasdaq
Low-intensity transcranial focused ultrasound amygdala neuromodulation: a double-blind sham-controlled target engagement study and unblinded single-arm clinical trial - Nature
Intensity Therapeutics Inc (INTS)’s stock performance: a year in review - uspostnews.com
Intensity Therapeutics Inc’s Bumpy Road: Analyzing the 52-Week Range and Future Prospects - investchronicle.com
INTS stock touches 52-week low at $1.49 amid market challenges - Investing.com Australia
Dow Jumps Over 1,000 Points; Tesla Shares Rise After Q1 Results - Benzinga
Intensity Therapeutics Highlights Cancer Treatment Progress - TipRanks
Is RollsRoyce (RYCEY) Stock Outpacing Its Aerospace Peers This Year? - Yahoo Finance
Is Cencora, Inc. (COR) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Why ArcelorMittal (MT) is a Top Value Stock for the Long-Term - Yahoo Finance
Tesla Delays Launch of Cheaper, Stripped-Down Version of Model Y in US - Yahoo Finance
The Zacks Analyst Blog Highlights Affirm, StoneCo, ACI Worldwide, Coinbase Global and OppFi - Yahoo Finance
Brokers Suggest Investing in QuickLogic (QUIK): Read This Before Placing a Bet - Yahoo Finance
Intensity Therapeutics, Inc. Announces Pricing of $3 Million Registered Direct Offering and Concurrent Private Placement - Quantisnow
Jim Cramer: Cencora (COR) Is a “Must-Own” Drug Middleman – Even If It Should Be Digitized Away - Yahoo Finance
US Radiotherapy Market worth US$2.49 billion by 2030 with 4.6% CAGR | MarketsandMarkets™ - PR Newswire UK
US Radiotherapy Market worth US$2.49 billion by 2030 with 4.6% CAGR | MarketsandMarkets™. - The Manila Times
Relation of Low-Density Lipoprotein Cholesterol, High-Sensitivity C-Reactive Protein, and Lipoprotein(a) Each to Future Cardiovascular Events and Death After Acute Coronary Syndrome on High-Intensity Statin Therapy: An Analysis of the Placebo Arm of OD - American Heart Association Journals
IntercontinentalExchange price target lowered to $230 from $237 at BofA - Yahoo Finance
Has Cencora, Inc. (COR) Outpaced Other Medical Stocks This Year? - Yahoo Finance
Why Iridium Communications (IRDM) is a Top Value Stock for the Long-Term - Yahoo Finance
Soft Tissue Sarcoma Treatment Market Size in 7MM is expected - openPR.com
Insiders At Cencora Sold US$16m In Stock, Alluding To Potential Weakness - Yahoo Finance
Leading Factor Driving the Burkitt Lymphoma Therapeutics Market in 2025: Impact Of Rising HIV Incidence On ... - WhaTech
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Soft Tissue Sarcoma Clinical Pipeline | 70+ Companies Driving Innovation in Treatment - openPR
Benchmark maintains Speculative Buy on Intensity Therapeutics By Investing.com - Investing.com South Africa
Finanzdaten der Intensity Therapeutics Inc-Aktie (INTS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.84%
0.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):